You are here

FDA Questions Treatment for Immune Deficiency Disorders

HyQ is an investigational product that includes plasma-derived immune globulin 10% and Halozyme's recombinant human hyaluronidase (rHuPH20) for subcutaneous administration in patients with primary immunodeficiency disease.

The FDA’s letter requested additional preclinical data to support the BLA. The primary issues raised in the letter focused on non-neutralizing antibodies generated against recombinant human hyaluronidase and the possible effects of these antibodies on reproduction, development, and fertility. Elevated anti-rHuPH20 antibody titers were detected in the registration trial but have not been associated with adverse events.

While waiting for the companies to provide additional data, CBER has directed that patients should no longer be dosed with rHuPH20 in the Baxter and ViroPharma clinical studies.

Read the news release on Halozyme's Web site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs